Federal Register / Vol. 76, No. 160 / Thursday, August 18, 2011 / Notices 51375 

identification of viral epitopes is 

critically important to understanding 

immune responses to infection and 

vaccination, and there are currently no 

comparable methods besides the classic 

screening of vast arrays of overlapping 

viral peptides on blood lymphocytes. 

Peptide screening methods only identify 

possible target epitopes, but do not 

define which epitopes are expressed in 

lung tissue. The technology will be 

valuable for vaccine development and 

evaluation, and has the flexibility to 

allow rapid analysis of novel pandemic 

strains for immunogenic epitopes. The 

technology can be applied to other 

infectious diseases, cancer, and 

immunotoxicities. 

II. Award Information/Funds Available 

A. Award Amount 

Only one grant award will be made in 

fiscal year (FY) 2012. The application 

budget is not limited, but it needs to 

reflect the actual needs of the proposed 

project. However, presently for FY 2012, 

the funds are available in the amount of 

$400,000 (total cost), and are subject to 

change based on the availability of 

funds. 

B. Length of Support 

The maximum period is 1 year with 

the option of 4 more years of budget 

support depending on the availability of 

funds. 

III. Paper Application, Registration, 

and Submission Information 

To submit a paper application in 

response to this FOA, applicants should 

first review the full announcement 

located at http://www.fda.gov/ 

AboutFDA/CentersOffices/CDER/ 

ucm088761.htm. Persons interested in 

applying for a grant may obtain an 

application at http://grants2.nih.gov/ 

grants/funding/phs398/phs398.html. 

For all paper application submissions, 

the following steps are required: 

• Step 1: Obtain a Dun and Bradstreet 

(DUNS) Number. 

• Step 2: Register With Central 

Contractor Registration. 

• Step 3: Register With Electronic 

Research Administration (eRA) 

Commons. 

Steps 1 and 2, in detail, can be found 

at http://www07.grants.gov/applicants/ 

organization_registration.jsp. Step 3, in 

detail, can be found at https:// 

commons.era.nih.gov/commons/ 

registration/registrationInstructions.jsp. 

After you have followed these steps, 

submit paper applications to: Gladys 

Bohler, Grants Management Specialist 

(see FOR FURTHER INFORMATION CONTACT

section of this document). 

Dated: August 9, 2011. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2011–21043 Filed 8–17–11; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2011–N–0002] 

Dialogues in Diversifying Clinical 

Trials: Successful Strategies for 

Engaging Women and Minorities in 

Clinical Trials 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of meeting. 

The Food and Drug Administration 

(FDA) is announcing the following 

Office of Women’s Health and Society 

for Women’s Health Research jointly 

sponsored meeting: Dialogues in 

Diversifying Clinical Trials: Successful 

Strategies for Engaging Women and 

Minorities in Clinical Trials. The 

purpose of this symposium is to 

facilitate the broader discussion and 

dissemination of innovative strategies 

for increasing the recruitment and 

retention of women and minority 

subpopulations into clinical trials. The 

overarching goal of this symposium is to 

use a best practices learning exchange to 

share information and encourage 

successful methods and/or model 

implementation within a broad research 

community—industry, academia, and 

government. 

Date and Time: The meeting will be 

held on September 22, 2011, from 8 a.m. 

to 9 a.m. (registration); 9 a.m. to 5:30 

p.m. (program); 5:30 p.m. to 6:30 p.m. 

(reception); and September 23, from 8 

a.m. to 1:30 p.m. 

Location: The meeting will be held at 

L’Enfant Plaza Hotel, 480 L’Enfant 

Plaza, SW., Washington, DC 20024. 

Contact: Deborah Kallgren, FDA 

Office of Women’s Health, 10903 New 

Hampshire Ave., Bldg. 32, Rm. 2314, 

Silver Spring, MD 20993–0002, 301– 

796–9442, Fax: 301–847–8604, e-mail: 

deborah.kallgren@fda.hhs.gov. 

Registration: Registration is free, but 

seating is limited to 200. Registration 

will be accepted online and is available 

at http://www.swhr.org through 

September 16, 2011. For information 

regarding registration contact: Rachel 

Griffith, Society for Women’s Health 

Research (SWHR), 1025 Connecticut 

Ave., NW., Suite 701, Washington, DC 

20036, 202–496–5001, Fax: 202–833– 

3472, e-mail: rachel@swhr.org. 

If you need special accommodations 

due to a disability, please contact 

Rachel Griffith at least 7 days in 

advance. 

Dated: August 12, 2011. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2011–21042 Filed 8–17–11; 8:45 am] 

BILLING CODE 4160–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Secretary’s Advisory Committee on 

Heritable Disorders in Newborns and 

Children; Notice of Meeting 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463, codified at 5 U.S.C. 

App. 2), notice is hereby given of the 

following meeting: 

Name: Secretary’s Advisory 

Committee on Heritable Disorders in 

Newborns and Children. 

Dates and Times: September 22, 2011, 

8:30 a.m. to 5 p.m.; September 23, 2011, 

8:30 a.m. to 3:30 p.m. 

Place: Renaissance Washington, DC 

DuPont Circle Hotel, 1143 New 

Hampshire Avenue, NW., Washington, 

DC 20037. 

Status: The meeting will be open to 

the public with attendance limited due 

to space availability. Participants are 

asked to register for the meeting by 

going to the registration Web site at 

http://altarum.cvent.com/event/ 

SACHDNC092011. The registration 

deadline is Tuesday, September 20, 

2011. Individuals who need special 

assistance, such as sign language 

interpretation or other reasonable 

accommodations, should indicate their 

needs on the registration website. The 

deadline for special accommodation 

requests is Friday, September 19, 2011. 

If there are technical problems gaining 

access to the Web site, please contact 

Maureen Ball, Meetings Coordinator, at 

conferences@altarum.org. 

Purpose: The Secretary’s Advisory 

Committee on Heritable Disorders in 

Newborns and Children (Advisory 

Committee) was established by Congress 

to advise and guide the Secretary 

regarding the most appropriate 

application of universal newborn 

screening tests, technologies, policies, 

guidelines and programs for effectively 

reducing morbidity and mortality in 

newborns and children having (or at 

risk) for heritable disorders. The 

Advisory Committee, as authorized by 

Public Law 106–310, which added 

mstockstill on DSK4VPTVN1PROD with NOTICES